Lucatumumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD40 |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 903512-50-5  |
| ATC code | None |
| UNII | P0EP9VFC4R  |
| KEGG | D08942 |
| Chemical data | |
| Formula | ? |
| Mol. mass | 146 kDa |
 (what is this?) (verify) |
|
Lucatumumab is a human monoclonal antibody[1] being investigated for the treatment of various types of cancer like multiple myeloma,[2] non-Hodgkin's or Hodgkin's lymphoma.[3]
This drug was developed by Novartis Pharmaceuticals Corp.
[edit] References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
- ^ ClinicalTrials.gov NCT00231166
- ^ ClinicalTrials.gov NCT00670592
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
